Galaxy Therapeutics Appoints Neurovascular Industry Expert, Dr. Michael Alexander, as Chief Medical Officer

Newest Addition in Line with the Company's Stated Goal of Expanding its Clinical and Scientific Teams as it Progresses Development and Ultimate Commercialization of its SEAL™ Device to Treat Brain Aneurysms  

MILPITAS, Calif.  , June 18, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced that Dr. Michael Alexander, a highly distinguished specialist in the field of neurosurgery, has joined the company in the newly created position of Chief Medical Officer. In this role, Dr. Alexander will provide global medical leadership across the company's clinical development programs, including the ongoing Saccular Endovascular Aneurysm Lattice (SEAL^™) IT IDE trial and future studies focused on treating complex brain aneurysms with the SEAL device.

Dr. Alexander is a dual-trained cerebrovascular neurosurgeon and neurointerventionalist with over two decades of leadership in clinical research and patient care. Since 2007, he has been affiliated with Cedars-Sinai in Los Angeles, where his most recent roles include Professor and Vice Chair of Neurosurgery, Co-Director, Cedars-Sinai Medical Center Comprehensive Stroke Center, Director, Cedars-Sinai Neurovascular Center and Staff Physician IV (Neurosurgery). While there, he also served as the Team Neurosurgeon for the Los Angeles Rams during the organization's 2016-2017 season. Before joining Cedars-Sinai, Dr. Alexander spent seven years as an Associate Professor at Duke University Medical Center and earlier, as a Fellow at the UCLA Medical Center. Dr. Alexander will continue to serve in his current academic and clinical roles while contributing his expertise to Galaxy's strategic and scientific growth.

"Dr. Alexander's unmatched clinical trial experience, scientific rigor, and stellar reputation in the neurointerventional community make him an ideal Chief Medical Officer," said Dr. Sam Zaidat, President and Chief Executive Officer of Galaxy Therapeutics. "As such, we are honored to welcome him to the executive team and are confident that he will be instrumental in helping us bring our technology to patients, worldwide. I have long admired his contributions to the field and am excited to now work alongside him to advance our mission."

Dr. Zaidat also noted that Galaxy Therapeutics will continue to expand its clinical and scientific leadership team as it accelerates the development and regulatory path of its innovative SEAL device, designed to address the most challenging aneurysm anatomies.

During his career, Dr. Alexander has participated in more than 45 clinical trials and, notably, has been a continuously funded investigator by the National Institutes of Health (NIH) for the past 18 years. He is a Past President of the Society of NeuroInterventional Surgery (SNIS), co-author of two textbooks, and has published more than 160 peer-reviewed articles in the field of neurovascular disease. Dr. Alexander received his M.D. from Georgetown University School of Medicine and completed Fellowships in Neurovascular and Skull Base Surgery from Barrow Neurological Institute and in NeuroIntervention from David Geffen School of Medicine at UCLA.

About Galaxy Therapeutics
Galaxy Therapeutics is a private, U.S.-based clinical-stage medical device company founded by four practicing neurointerventional physicians. The company has developed a novel implant technology for the treatment of brain aneurysms and holds multiple patents across the U.S., EU, China, and other key markets. Headquartered in Milpitas, California, Galaxy Therapeutics is advancing multiple clinical programs globally and is committed to delivering effective, evidence-based solutions to physicians and patients.

For more information, visit www.galaxytherapeutics.com, follow the company on LinkedIn or contact: 
contact@gtseal.com

Logo: https://mma.prnewswire.com/media/2698518/5343025/Galaxy_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/galaxy-therapeutics-appoints-neurovascular-industry-expert-dr-michael-alexander-as-chief-medical-officer-302485228.html

SOURCE Galaxy Therapeutics